Breaking News Instant updates and real-time market news.

RRC

Range Resources

$3.49

-0.15 (-4.12%)

, AG

First Majestic

$10.70

0.14 (1.33%)

08:45
12/02/19
12/02
08:45
12/02/19
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Range Resources (RRC) 1.84% +0.37, First Majestic Silver (AG) 2.02% +0.32, Financial Bear 3X (FAZ) 9.72% +0.24, Yamana Gold (AUY) 0.45% +0.20, ProShares Short VIX Short Term Futures (SVXY) 4.66% +0.19, National Beverage (FIZZ) 2.52% +0.12, Juniper Networks (JNPR) 0.65% +0.09, SPDR S&P Regional Banking (KRE) 1.33% +0.08, Wells Fargo (WFC) 0.30% +0.05, and Neurocrine (NBIX) 0.29% +0.04.

RRC

Range Resources

$3.49

-0.15 (-4.12%)

AG

First Majestic

$10.70

0.14 (1.33%)

FAZ

Direxion Financial Bear 3x

$29.33

0.17 (0.58%)

AUY

Yamana Gold

$3.61

0.11 (3.14%)

SVXY

ProShares Short VIX Short-Term Futures

$63.04

-0.7 (-1.10%)

FIZZ

National Beverage

$49.64

0.24 (0.49%)

JNPR

Juniper

$25.08

0.19 (0.76%)

KRE

SPDR S&P Regional Banking ETF

$56.24

-0.32 (-0.57%)

WFC

Wells Fargo

$54.40

0.05 (0.09%)

NBIX

Neurocrine

$116.64

-1.11 (-0.94%)

  • 02

    Dec

  • 03

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 12

    Dec

  • 14

    Jan

RRC Range Resources
$3.49

-0.15 (-4.12%)

10/04/19
FBCO
10/04/19
DOWNGRADE
Target $4
FBCO
Neutral
Range Resources downgraded to Neutral from Outperform at Credit Suisse
As previously reported, Credit Suisse analyst Betty Jiang downgraded Range Resources to Neutral and also lowered her price target to $4 from $8. The analyst warns that at current strip prices, the company's net debt to EBITDX ratio will rise from 3.2-times in 2018 to 3.9-times this year and to about 4.5-times over the next two years, which is "well above" its long term target and peer group average of 2-times. Jiang adds that under current prices, Range Resources will require a "much larger" $2B in non-producing sales to achieve that 2-times target, but given the outlook for lower than assumed prices, the management will likely go into "maintenance capex mode" in 2020.
10/03/19
FBCO
10/03/19
DOWNGRADE
FBCO
Neutral
Range Resources downgraded to Neutral from Outperform at Credit Suisse
08/26/19
LTCO
08/26/19
DOWNGRADE
Target $5
LTCO
Neutral
Range Resources downgraded to Neutral from Buy at Ladenburg
Ladenburg Thalmann analyst Michael Schmitz downgraded Range Resources to Neutral from Buy and lowered his price target for the shares to $5 from $11. Reduced estimated free cash flow resulting from lower projected commodity prices, combined with uncertainty resulting from the escalation of the trade war, will be additional headwinds for the Exploration and Production group, Schmitz tells investors in a research note.
08/19/19
MKMP
08/19/19
UPGRADE
Target $6
MKMP
Buy
Range Resources rises following MKM Partners upgrade
As reported prior to the open, MKM Partners upgraded Range Resources (RRC) to Buy from Neutral with an unchanged price target of $6. Analyst John Gerdes noted that Range shares have shed two-thirds in value since mid-January despite the fact that the company's full-cycle return is "meaningfully superior" to median cash recycle ratio of its gas peers and its full-cycle capital intensity is second lowest to only Cabot Oil & Gas (COG). His production forecast for Range for the third quarter is fractionally above the company's guidance, though is production estimate for the full year is fractionally below Range's guidance, Gerdes noted. In afternoon trading, shares of Range Resources are up 38c, or 9%, to $4.48.
AG First Majestic
$10.70

0.14 (1.33%)

02/28/19
RILY
02/28/19
INITIATION
Target $6
RILY
Neutral
First Majestic initiated with a Neutral at B. Riley FBR
B. Riley FBR analyst Adam Graf started First Majestic Silver with a Neutral rating and $6 price target. The stock looks ahead of itself based on current silver prices, Graf tells investors in a research note.
01/15/19
BMOC
01/15/19
DOWNGRADE
BMOC
Market Perform
First Majestic downgraded to Market Perform from Outperform at BMO Capital
As reported earlier, BMO Capital analyst Ryan Thompson downgraded First Majestic to Market Perform and lowered his price target to C$8.25 from C$8.50. The analyst cites the company's lower than expected output in Q4 and also softer than anticipated guidance for FY19 amid a slowdown in production at Del Toro site and continued declines at La Parilla. Thompson adds that First Majestic has "underspent" on exploration in recent years and is now forced to play "catch-up".
01/15/19
BMOC
01/15/19
DOWNGRADE
BMOC
Market Perform
First Majestic downgraded to Market Perform from Outperform at BMO Capital
01/14/19
BMOC
01/14/19
DOWNGRADE
BMOC
Market Perform
First Majestic downgraded to Market Perform from Outperform at BMO Capital
BMO Capital analyst Ryan Thompson downgraded First Majestic to Market Perform from Outperform and lowered his price target to C$8.25 from C$8.50.
FAZ Direxion Financial Bear 3x
$29.33

0.17 (0.58%)

AUY Yamana Gold
$3.61

0.11 (3.14%)

10/14/19
FBCO
10/14/19
INITIATION
Target $4.5
FBCO
Outperform
Yamana Gold assumed with an Outperform at Credit Suisse
Credit Suisse analyst Fahad Tariq assumed coverage of Yamana Gold with an Outperform rating and $4.50 price target. The analyst made no changes to the firm's estimates, rating or target price in conjunction with the assumption of primary coverage.
04/18/19
NATB
04/18/19
DOWNGRADE
NATB
Sector Perform
Yamana Gold downgraded to Sector Perform from Outperform at National Bank
04/26/19
RBCM
04/26/19
DOWNGRADE
RBCM
Sector Perform
Yamana Gold downgraded to Sector Perform from Outperform at RBC Capital
06/28/19
NATB
06/28/19
UPGRADE
NATB
Outperform
Yamana Gold upgraded to Outperform from Sector Perform at National Bank
SVXY ProShares Short VIX Short-Term Futures
$63.04

-0.7 (-1.10%)

FIZZ National Beverage
$49.64

0.24 (0.49%)

11/11/19
JEFF
11/11/19
NO CHANGE
Target $30
JEFF
Underperform
National Beverage estimates and price target lowered at Jefferies
Jefferies analyst Kevin Grundy lowered his estimates for National Beverage (FIZZ) saying Coca-Cola's (KO) new sparkling water brand "should be a wake-up call." Post PepsiCo's (PEP) successful launch of the bubly brand in 2018, Coca-Cola will be playing catch-up in the fast-growing sparkling water space with its first major brand launch since 2006, Grundy tells investors in a research note. He believes "bigger and bolder decisions" are called for at National Beverage, which he says has been slow to respond with its "once-leading" La Croix brand. Grundy lowered his price target for the shares to $30 from $32 and keeps an Underperform rating on National Beverage.
11/18/19
GUGG
11/18/19
NO CHANGE
Target $31
GUGG
Sell
Coca-Cola's 'AHA' likely to take shelf space from LaCroix, says Guggenheim
Guggenheim analyst Laurent Grandet said he expects National Beverage's (FIZZ) LaCroix brand to likely lose shelf space and market share to Coca-Cola's (KO) upcoming "AHA" brand of flavored sparkling waters, which are launching in March 2020, and he lowered his EPS estimates in FY21 and FY22 accordingly. He continues to think LaCroix will not stabilize until at least next year, given increased competition and what he sees as a lack of meaningful innovation, and Grandet keeps a Sell rating on shares of parent National Beverage, trimming his price target on the stock to $31 from $32.
07/01/19
IMPC
07/01/19
NO CHANGE
Target $65
IMPC
Outperform
National Beverage price target lowered to $65 from $150 at Imperial Capital
Imperial Capital analyst George Kelly lowered his price target for National Beverage to $65 from $150 but maintains an Outperform rating on the shares. While scanner data trends remain mixed and the company has had a challenging year, its brands have value and the the sparkling water category is seeing continued momentum, Kelly tells investors in a research note. The analyst reduced his estimates to account for National Beverage's growth and margin pressures. However, its is important to note that projecting revenue growth is challenging given the company's limited disclosure and choppy scanner data trends, adds the analyst.
06/27/19
GUGG
06/27/19
NO CHANGE
Target $34
GUGG
Sell
Guggenheim says National Beverage won't stabilize LaCroix until at least 2020
Guggenheim analyst Laurent Grandet keeps a Sell rating on National Beverage and lowered his price target on the stock to $34 from $36 following the company's Q4 report, which he said confirmed his expectations that the LaCroix brand "is now in precipitous decline." Grandet thinks LaCroix will not stabilize until at least next year given what he sees as its impaired brand image, along with increased competition and a "lack of meaningful or disruptive innovation."
JNPR Juniper
$25.08

0.19 (0.76%)

10/22/19
JPMS
10/22/19
UPGRADE
Target $27
JPMS
Neutral
Juniper upgraded to Neutral on stabilizing sales trends at JPMorgan
JPMorgan analyst Samik Chatterjee upgraded Juniper Networks to Neutral from Underweight with a price target of $27, up from $25. Stabilizing sales trends limit further downside to the shares, which are already trading at an inexpensive valuation, Chatterjee tells investors in a research note. Further, Juniper has "optionality to several upside opportunities," including Campus from the strong adoption of Mist Systems as well as datacom optics and 400G switching to hyperscale customers, contends the analyst. Chatterjee, who is still only forecasting modest single-digit revenue growth medium-term, says Juniper appears to be cycling past the worst in terms of revenue declines. As such, he sees a more balanced risk/reward for the shares.
11/12/19
RBCM
11/12/19
INITIATION
Target $27
RBCM
Sector Perform
Juniper assumed with a Sector Perform at RBC Capital
RBC Capital analyst Robert Muller assumed coverage of Juniper with a Sector Perform rating and $27 price target.
11/12/19
RBCM
11/12/19
INITIATION
Target $27
RBCM
Sector Perform
Juniper assumed with a Sector Perform at RBC Capital
RBC Capital analyst Robert Muller assumed coverage of Juniper Networks with a Sector Perform rating and $27 price target. The analyst is cautious on the extent that Juniper can win hyperscale business and resume growth in its telecom vertical. He remains Sector Perform rated pending signs that the company "has made successful inroads."
10/22/19
JPMS
10/22/19
UPGRADE
Target $27
JPMS
Neutral
Juniper upgraded to Neutral from Underweight at JPMorgan
JPMorgan analyst Samik Chatterjee upgraded Juniper Networks to Neutral from Underweight with a $27 price target.
KRE SPDR S&P Regional Banking ETF
$56.24

-0.32 (-0.57%)

WFC Wells Fargo
$54.40

0.05 (0.09%)

12/02/19
RAJA
12/02/19
DOWNGRADE
RAJA
Underperform
Raymond James downgrades Wells Fargo to Underperform on expected earnings cuts
Raymond James analyst David Long downgraded Wells Fargo to Underperform from Market Perform without a price target. Negative earnings revisions will provide a headwind for Wells Fargo's shares, Long tells investors in a research note. The analyst, whose estimates are now below consensus, expects the bank's revenue to contract for the fourth straight year in 2020. Further, he believes Wells' profitability metrics will remain below-peer and that any profitability improvement plan initiated by new CEO Charlie Scharf would reduce earnings estimates before becoming accretive.
12/02/19
RAJA
12/02/19
DOWNGRADE
RAJA
Underperform
Wells Fargo downgraded to Underperform from Market Perform at Raymond James
Raymond James analyst David Long downgraded Wells Fargo to Underperform from Market Perform.
11/15/19
ROTH
11/15/19
DOWNGRADE
Target $8
ROTH
Neutral
Mitek Systems downgraded on USAA litigation risk at Roth Capital
Roth Capital analyst Darren Aftahi downgraded Mitek Systems (MITK) to Neutral from Buy with a price target of $8, down from $12.50. The potential "trickle-down litigation risk" from USAA against Mitek's mobile deposit customer's acts is "too big of a risk/uncertainty to shares," Aftahi tells investors in a research note. He believes this could drag on for an extended period of time, causing distraction and additional legal costs. While Mitek does not believe it is the target of a lawsuit from USAA, the ruling in favor of USAA against Wells Fargo (WFC) could prove to be too big of a risk to justify buying Mitek shares currently, says Aftahi.
10/22/19
ODEN
10/22/19
DOWNGRADE
ODEN
Hold
Wells Fargo downgraded to Hold from Buy at Odeon Capital
Odeon Capital analyst Richard Bove downgraded Wells Fargo to Hold from Buy despite his view of the bank as "one of the most powerful companies in the United States" in spite of "all of its problems and all of its challenges." However, Wells' net interest margins will remain under pressure, sending its net interest income lower, while its costs are unlikely to decline any time soon and it faces more legal and regulatory issues, Bove tells investors.
NBIX Neurocrine
$116.64

-1.11 (-0.94%)

11/05/19
PIPR
11/05/19
NO CHANGE
Target $116
PIPR
Overweight
Neurocrine price target raised to $116 from $111 at Piper Jaffray
Piper Jaffray analyst David Amsellem raised his price target for Neurocrine Biosciences to $116 from $111 saying the company reported another "impressive quarter" for Ingrezza. He continues to believe that peak U.S. sales potential in the $2B-plus neighborhood are realistic and reiterates an Overweight rating on the shares.
10/04/19
GUGG
10/04/19
NO CHANGE
GUGG
Guggenheim positively biased on Biotech heading into earnings
Guggenheim analysts Whitney Ijem, Etzer Darout, Yatin Suneja and Michael Schmidt offered a preview for their joint Biotech coverage ahead of the group's earnings reporting season. Biotech stocks continued their downward trend in the quarter amid negative market sentiment and the analysts think the bar for companies to raise 2019 guidance again may be a bit higher following increases in FY19 consensus estimates on the heels of strong Q2 earnings results. However, they are postively biased on the group and have confidence in FY19 guidance and estimates, the analysts said. They see Alexion (ALXN), Biogen (BIIB), Genmab (GMAB), GW Pharmaceuticals (GWPH), Incyte (INCY), Neurocrine (NBIX), Regeneron (REGN) and Seattle Genetics (SGEN) as well positioned relative to expectations, Ijem, Darout, Suneja and Schmidt tell investors.
08/28/19
GSCO
08/28/19
NO CHANGE
Target $110
GSCO
Buy
Slower Orilissa ramp has minimal impact on Neurocrine, says Goldman Sachs
To reflect the slower than expected ramp in sales of Orilissa in endometriosis, Goldman Sachs analyst Paul Choi lowered his Neurocrine Biosciences (NBIX) forecasts of Orilissa royalties. He projects similar 40% market share by 2026 for both Myovant Sciences' (MYOV) relugolix and Orilissa within endometriosis and uterine fibroid patients treated with a GnRH receptor antagonists. However, in the near-term, since Orilissa royalties are a small fraction of Neurocrine's revenue, these changes have little impact on the company's top- and bottom- lines, says Choi. As such, the analyst keeps a Buy rating on Neurocrine Biosciences with a $110 price target.
09/25/19
RBCM
09/25/19
NO CHANGE
RBCM
Outperform
Neurocrine approval in Huntington's could add upside, says RBC Capital
RBC Capital analyst Brian Abrahams noted that a posting to the ClinicalTrials.gov site revealed that Neurocrine Biosciences is studying the use of Ingrezza in the treatment of Huntington's Chorea. He thinks that Ingrezza's strong position in the tardive dyskinesia market could be a boon for the drug in a new indication and predicts that eventual approval in Huntington's could potentially add as much as an added 20% to out-year revenue estimates for the drug. Abrahams keeps an Outperform rating on Neurocrine shares.

TODAY'S FREE FLY STORIES

02:05
12/11/19
12/11
02:05
12/11/19
02:05
General news
FOMC Preview: »

FOMC Preview: No policy…

01:45
12/11/19
12/11
01:45
12/11/19
01:45
General news
Asian Market Update: »

Asian Market Update:…

ACB

Aurora Cannabis

$2.52

-0.095 (-3.63%)

21:25
12/10/19
12/10
21:25
12/10/19
21:25
Conference/Events
Aurora Cannabis management to meet with Cantor Fitzgerald. »

Analyst Pablo Zuanic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

SPY

SPDR S&P 500 ETF Trust

$313.58

-0.29 (-0.09%)

, SPX

S&P 500

$0.00

(0.00%)

21:00
12/10/19
12/10
21:00
12/10/19
21:00
General news
White House Navarro says 'no indication' Dec 15th tariffs will be delayed »

Comments made on Fox…

SPY

SPDR S&P 500 ETF Trust

$313.58

-0.29 (-0.09%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$38.07

0.025 (0.07%)

20:35
12/10/19
12/10
20:35
12/10/19
20:35
Hot Stocks
AT&T sets 2020 cost cut target of 4%, enters into accelerated $4B buyback »

John Stankey, COO of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

  • 29

    Jan

AEO

American Eagle

$15.13

-0.21 (-1.37%)

, PLCE

Children's Place

$70.67

0.68 (0.97%)

20:25
12/10/19
12/10
20:25
12/10/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

AEO

American Eagle

$15.13

-0.21 (-1.37%)

PLCE

Children's Place

$70.67

0.68 (0.97%)

UNFI

United Natural Foods

$9.88

0.19 (1.96%)

VRA

Vera Bradley

$12.05

-0.09 (-0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

  • 11

    Dec

  • 11

    Dec

  • 18

    Dec

SAGE

Sage Therapeutics

$63.23

0.55 (0.88%)

20:15
12/10/19
12/10
20:15
12/10/19
20:15
Hot Stocks
Sage Therapeutics CSO buys 25K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAGE

Sage Therapeutics

$63.23

0.55 (0.88%)

20:14
12/10/19
12/10
20:14
12/10/19
20:14
Hot Stocks
Sage Therapeutics CEO buys 7.5K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XP

XP

$0.00

(0.00%)

20:11
12/10/19
12/10
20:11
12/10/19
20:11
Syndicate
XP 72.5M share IPO priced at $27.00 »

The deal priced above the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

PMT

PennyMac Mortgage

$22.75

-0.055 (-0.24%)

20:08
12/10/19
12/10
20:08
12/10/19
20:08
Syndicate
PennyMac Mortgage 8M share Spot Secondary priced at $22.10 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

SALM

Salem Media

$1.49

0.03 (2.05%)

19:48
12/10/19
12/10
19:48
12/10/19
19:48
Hot Stocks
Salem Media cuts quarterly dividend to 2.5c from 6.5c per share »

The cash distribution…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HROW

Harrow Health

$6.74

0.21 (3.22%)

19:46
12/10/19
12/10
19:46
12/10/19
19:46
Hot Stocks
Surgical Eyedrop wins return of patent from Harrow Health »

Novel Drug Solutions and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZUMZ

Zumiez

$34.02

-0.67 (-1.93%)

19:32
12/10/19
12/10
19:32
12/10/19
19:32
Hot Stocks
Zumiez director sells 5.8K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRC

Tejon Ranch

$16.07

0.02 (0.12%)

18:47
12/10/19
12/10
18:47
12/10/19
18:47
Hot Stocks
Ken County board of supervisors reaffirms approval of Grapevine at Tejon Ranch »

By a 5-0 vote, the Kern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXTR

Extreme Networks

$6.89

0.02 (0.29%)

, AVGO

Broadcom

$315.10

0.61 (0.19%)

18:43
12/10/19
12/10
18:43
12/10/19
18:43
Hot Stocks
Extreme Networks CEO: We've always been software driven »

In an interview on…

EXTR

Extreme Networks

$6.89

0.02 (0.29%)

AVGO

Broadcom

$315.10

0.61 (0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 12

    Dec

WDFC

WD-40

$194.80

-0.94 (-0.48%)

18:36
12/10/19
12/10
18:36
12/10/19
18:36
Hot Stocks
WD-40 names Garry Ridge as new board Chairman »

WD-40 announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

ASPU

Aspen Group

$7.00

0.02 (0.29%)

, OLLI

Ollie's Bargain Outlet

$60.28

(0.00%)

18:34
12/10/19
12/10
18:34
12/10/19
18:34
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Aspen…

ASPU

Aspen Group

$7.00

0.02 (0.29%)

OLLI

Ollie's Bargain Outlet

$60.28

(0.00%)

PLAY

Dave & Buster's

$40.07

-0.2 (-0.50%)

PLT

Plantronics

$22.93

-0.44 (-1.88%)

CHH

Choice Hotels

$97.40

-0.03 (-0.03%)

LDOS

Leidos

$89.63

-0.47 (-0.52%)

GME

GameStop

$6.50

0.18 (2.85%)

CORV

Correvio

$1.39

(0.00%)

AQST

Aquestive Therapeutics

$7.60

-0.14 (-1.81%)

KIDS

OrthoPediatrics

$38.40

-0.35 (-0.90%)

MDGL

Madrigal Pharmaceuticals

$118.45

1.16 (0.99%)

RCKT

Rocket Pharmaceuticals

$24.22

1.22 (5.30%)

MNTA

Momenta

$18.09

0.19 (1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

  • 10

    Dec

  • 10

    Dec

  • 10

    Dec

  • 13

    Dec

  • 16

    Dec

  • 24

    Dec

  • 30

    Dec

NFLX

Netflix

$293.21

-9.27 (-3.06%)

, UBER

Uber

$27.89

0.18 (0.65%)

18:27
12/10/19
12/10
18:27
12/10/19
18:27
Periodicals
Peru seeks sales taxes from Netflix, Uber, Spotify, Reuters says »

Claudia Suarez of the…

NFLX

Netflix

$293.21

-9.27 (-3.06%)

UBER

Uber

$27.89

0.18 (0.65%)

SPOT

Spotify

$145.73

-0.71 (-0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

UBS

UBS

$11.95

-0.07 (-0.58%)

18:25
12/10/19
12/10
18:25
12/10/19
18:25
Periodicals
Judge rebuffs UBS' effort to reject U.S. lawsuit, Reuters reports »

U.S. District Judge Margo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

18:25
12/10/19
12/10
18:25
12/10/19
18:25
General news
Treasury Market Summary »

Treasury Market Summary:…

AKS

AK Steel

$3.41

0.08 (2.40%)

, MT

ArcelorMittal

$17.66

-0.05 (-0.28%)

18:22
12/10/19
12/10
18:22
12/10/19
18:22
Hot Stocks
USW union expresses support for new USMCA »

United Steelworkers…

AKS

AK Steel

$3.41

0.08 (2.40%)

MT

ArcelorMittal

$17.66

-0.05 (-0.28%)

NUE

Nucor

$57.76

0.005 (0.01%)

STLD

Steel Dynamics

$34.89

-0.21 (-0.60%)

X

U.S. Steel

$13.88

-0.215 (-1.53%)

TMST

TimkenSteel

$7.23

0.12 (1.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHH

Choice Hotels

$97.40

-0.03 (-0.03%)

, PLT

Plantronics

$22.93

-0.44 (-1.88%)

18:16
12/10/19
12/10
18:16
12/10/19
18:16
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

Choice Hotels…

CHH

Choice Hotels

$97.40

-0.03 (-0.03%)

PLT

Plantronics

$22.93

-0.44 (-1.88%)

VSI

Vitamin Shoppe

$6.50

0.005 (0.08%)

FRG

Franchise Group

$14.39

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

XP

XP

$0.00

(0.00%)

18:10
12/10/19
12/10
18:10
12/10/19
18:10
Syndicate
Breaking Syndicate news story on XP »

XP prices IPO at $27,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

MSFT

Microsoft

$151.18

-0.17 (-0.11%)

17:50
12/10/19
12/10
17:50
12/10/19
17:50
Hot Stocks
Microsoft, NTT in strategic alliance for enterprise digital transformation »

NTT Corporation and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

GLD

SPDR Gold Shares

$137.96

0.37 (0.27%)

17:45
12/10/19
12/10
17:45
12/10/19
17:45
Hot Stocks
SPDR Gold Shares holdings fall to 885.93MT from 886.23MT »

This is the lowest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.